Foolish Review: Vertex Earnings

In the following video, Motley Fool health-care analyst David Williamson takes a look back at Vertex's earnings report this quarter. While it was far from a good quarter for the company, things were somewhat better than expected, leading to a sell-off that wasn't nearly as bad as analysts had feared. David tells us why the company struggled this quarter, and what investors can expect from them in the months to come.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report, "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Foolish Review: Vertex Earnings originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.